Table 4.
Bivariate and multivariate analyses of factors associated with ≥ HSILs.
| Factors | HIV-MSM with ≥ HSIL (n = 17) |
HIV-MSM without ≥ HSIL (n = 107) |
*p | RR; (95% CI) |
|---|---|---|---|---|
| q-HPV Vaccine, n (%) | 9 (52.9) | 55 (50.9) | 0.877 | |
| Ab q-HPV Vaccine, n (%) | ||||
| 7 months | 9 (52.9) | 58 (54.2) | 0.92 | |
| 12 months | 8 (53.3) | 37 (45.1) | 0.56 | |
| 24 months | 2 (100) | 47 (54.7) | 0.2 | |
| 36 months | 1 (50) | 54 (60.7) | 1 | |
| 48 months | 0 | 53 (61.6) | 0.391 | |
| Titers Ab 7 m, median (IQR) | 2.21 (1.78–4.39) | 3.46 (1.7–5.1) | 0.41 | |
| Titers Ab 12 m, median (IQR) | 3.48 (2.26–3.65) | 2.39 (0–4.53) | 0.65 | |
| Interval between first dose and HSIL onset, IQR | 12 (12–12) | 48 (48–48) | 0.0001 | 0.869 (0.825–0.917) |
| Age; mean years (±SD) | 39 (10.98) | 38.54 (10.28) | 0.62 | |
| Median HR-HPV, (IQR) | 1 (0–4) | 1 (0–3) | 0.454 | |
| Median LR-HPV, (IQR) | 1 (0–2) | 1 (0–2) | 0.625 | |
| University education, n (%) | 8 (47.1) | 59 (54.6) | 0.626 | |
| Retired, n (%) | 2 (11.8) | 11 (10.2) | 0.69 | |
| Partners in previous 12 months; median (IQR) | 1 (0.5–2.5) | 1 (1–4) | 0.394 | |
| Life-time partners; median (IQR) | 100 (15–325) | 70 (22.75–300) | 0.988 | |
| Time since start of sexual activity (years); median (IQR) | 21 (11–28) | 18.5(10–27) | 0.552 | |
| Condom use, n (%) | 13 (76.5) | 84 (77.8) | 1 | |
| % condom use; median (IQR) | 99 (5–100) | 100 (52.5–100) | 0.289 | |
| Perianal/genital condyloma, n (%) | 7 (41.2) | 32 (29.6) | 0.4 | |
| History of condyloma, n (%) | 2 (11.8) | 31 (28.7) | 0.235 | |
| Smoking, n (%) | 10 (58.8) | 43 (38.9) | 0.12 | |
| Smoking, packs/year; median (IQR) | 2.7 (0–22) | 1.1 (0–12) | 0.267 | |
| Ex-smoker, n (%) | 2 (11.8) | 20 (18.5) | 0.497 | |
| Ex-IVDA, n (%) | 0 | 1 (0.9) | 1 | |
| Alcohol, consumer n (%) | 6 (35.3) | 57 (52.8) | 0.18 | |
| Alcohol (SDU), median, IQR | 0 (0–1.5) | 0.2 (0–1) | 0.397 | |
| Duration of HIV; mean (IQR) | 90 (52.5–214.5) | 61.5 (29.25–123.5) | 0.138 | |
| CD4 mean nadir; cells/µL (±SD) | 299.59 (261.1) | 341.4 (205.9) | 0.456 | |
| Naïve | 1 (5.9) | 9 (8.3) | 1 | |
| VL of HIV, log10(± SD) | 2.54 (3.12) | 3.79 (4.51) | 0.469 | |
| VL < 50 copies/mL, n (%) | 15 (88.2) | 87 (80.6) | 0.736 | |
| CD4 mean; cells/µL, (± SD) | 696.92 (215) | 729.01 (268.4) | 0.64 | |
| CD8 mean; cells/µL (± SD) | 1038.4 (273.4) | 995.6 (446) | 0.71 | |
| CD4/CD8 | 0.74 (0.29) | 1.4 (5.85) | 0.634 | |
| Previous AIDS diagnosis; n (%) | 8 (47.1) | 31 (28.7) | 0.129 | |
| Median duration of ART; months (IQR) | 51 (26.5–74) | 55 (23–111) | 0.214 | |
| Virological failure, n (%) | 0 | 4 (4) | 0.418 | |
| Syphilis, n (%) | 4 (23.5) | 22 (20.4) | 0.753 | |
| Other STD, n (%) | 2(11.8) | 20 (18.5) | 0.735 | |
| HCV, n (%) | 0 | 3 | 1 | |
| HBV, n (%) | 0 | 2 (1.9) | 1 | |
| AIN1 (1st HRA), n (%) | 9 (52.9) | 57 (52.8) | 0.99 | |
| HR-HPV baseline, n (%) | 13 (76.5) | 74 (73.3) | 1 | |
| LR-HPV baseline, n (%) | 11 (64.7) | 59 (58.4) | 0.625 | |
| HR and LR-HPV baseline, n (%) | 10 (58.8) | 47 (46.5) | 0.35 | |
| HPV at baseline visit | ||||
| HPV-6, n (%) | 3 (17.6) | 16 (15.8) | 1 | |
| HPV-11, n (%) | 3 (17.6) | 12 (11.9) | 0.452 | |
| HPV-16, n (%) | 5 (29.4) | 24 (23.8) | 0.761 | |
| HPV-18, n (%) | 1 (5.9) | 7 (6.9) | 1 | |
| HPV 12 months after first dose | ||||
| HPV-6, n (%) | 4 (23.5) | 22 (22.4) | 1 | |
| HPV-11, n (%) | 2 (11.8) | 13 (13.3) | 1 | |
| HPV-16, n (%) | 7 (41.2) | 37 (37.8) | 0.789 | |
| HPV-18, n (%) | 5 (29.4) | 11 (11.2) | 0.06 |
p*: p-value; p < 0.05. q-HPV vaccine: quadrivalent human papillomavirus vaccine; Ab q-HPV Vaccine: antibody to q-HPV vaccine. HRA: high resolution anoscopy. SDU: standard drink unit.